# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Calliditas Therapeutics AB (NASDAQ:CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open...
Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefeco...
Calliditas Therapeutics AB (NASDAQ:CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has ...
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics A...
Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has gran...
HC Wainwright & Co. analyst Arthur He reiterates Calliditas Therapeutics (NASDAQ:CALT) with a Buy and maintains $50 pric...
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday.